Enhanced Genomics has partnered with Cambridge University’s ALBORADA Drug Discovery Institute to identify novel therapeutic targets for Alzheimer’s disease using advanced 3D multi-omics technology. The collaboration has already yielded multiple previously undetectable targets, potentially accelerating drug discovery timelines across neurodegenerative diseases.
Logical Biological has established Logical Antigen, a specialist sister company focused on rapid customisation of high-quality antigens and biological materials. The new venture addresses critical supply chain challenges in the IVD market, offering streamlined protein purification services that reduce traditional development timelines from years to weeks through innovative extraction and engineering techniques.
Global nonprofit DEBRA Research has established a preclinical research collaboration with Queen Mary University of London to enhance drug development capabilities for epidermolysis bullosa, addressing critical bottlenecks in therapeutic advancement for this rare genetic skin disorder through innovative academic-philanthropic partnership models.
Cambridge-based 4basebio has launched refreshed branding and a new website following its £40 million investment round, as the AIM-listed company positions itself for growth in synthetic DNA manufacturing for next-generation therapeutics including gene therapy, RNA therapeutics and vaccine development.
Cherwell Laboratories, the established cleanroom microbiology specialist will transition to AnalytiChem UK from September 2025, marking the completion of its integration with the global AnalytiChem Group whilst maintaining its 54-year heritage in pharmaceutical manufacturing support and quality control solutions.
Clinical-stage radiopharmaceutical company ARTBIO has completed a substantial $132 million Series B financing round to advance its pipeline of alpha radioligand therapies, expand manufacturing capabilities, and support Phase II development of lead candidate AB001 for metastatic castration-resistant prostate cancer.
GEA’s new 40,000-square-metre facility in Elsdorf, Germany represents a strategic expansion into pharmaceutical freeze-drying systems, addressing surging global demand for vaccine and injectable drug manufacturing technologies. The investment demonstrates significant industry confidence in lyophilisation technology advancement.
Advancing clinical diagnostics through analytical excellence
Automated chemiluminescence immunoassay (ChLIA) systems are nowadays a mainstay for many diagnostic laboratories. Euroimmun has joined forces with Immunodiagnostic Systems (IDS) to offer an extensive portfolio of diagnostic solutions based on ChLIA technology. Clinical Laboratory International talked to Dr. Anna Stanisak, Global Product Manager for Automation at Euroimmun to find out more.
Congratulations to Finlay MacKenzie and Dr Rachel Marrington of Birmingham Quality [one of the main providers of clinical biochemistry external quality assessment (EQA) schemes in the UK] on receipt of their Impact Award presented at this year’s LabMedUK meeting in Manchester. This prestigious award recognizes their outstanding work on patient-centric EQA for acute kidney injury […]
March 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.